Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703088 | 0.95 | CYP4F2 (0.46) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL703499 | 0.86 | CYP4F2 (0.39) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL28886961 | 0.80 | CES2 (0.44) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL247768 | 0.80 | CES2 (0.44) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL6291594 | 0.80 | CYP4F2 (0.48) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL7758101 | 0.79 | CYP4F2 (0.42) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL18496504 | 0.78 | CYP4F2 (0.52) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL7055141 | 0.78 | CYP4F2 (0.52) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL7057707 | 0.78 | CYP4F2 (0.52) | CYP4F2CYP4A11CES2MEN1MAPT | |
| SCHEMBL7057733 | 0.78 | CYP4F2 (0.52) | CYP4F2CYP4A11CES2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148446-B2 | Silyl esters, their use in binder systems and paint compositions and a process of production thereof | SIGMAKALON B.V. (NL) | 2012-04-03 | — | — | US | claimed |
| US-20100249298-A1 | Silyl esters, their use in binder systems and paint compositions and a process of production thereof | GILLARD MICHEL | 2010-09-30 | — | — | US | claimed |
| US-8148446-B2 | Silyl esters, their use in binder systems and paint compositions and a process of production thereof | SIGMAKALON B.V. (NL) | 2012-04-03 | — | — | US | disclosed |
| US-20100249298-A1 | Silyl esters, their use in binder systems and paint compositions and a process of production thereof | GILLARD MICHEL | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249298-A1 | Silyl esters, their use in binder systems and paint compositions and a process of production thereof | LCT, PCMT1, TST | CYP4F2 1316/4885CYP4A11 672/4885CES2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.